AVROBIO develops and commercializes step-change cell and gene therapies for the treatment of cancer and rare diseases. Read more

71 Followers on Owler
71 Followers on Owler
71 Followers on Owler
71 Followers on Owler

AVROBIO develops and commercializes step-change cell and gene therapies for the treatment of cancer and rare diseases. Read more

Geoff MacKay's photo - President & CEO of AVROBIO

President & CEO

Geoff MacKay

CEO Approval Rating

98/100

Founded:

2015

Status:

PublicIndependent CompanyNASDAQAVRO

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Immune Design is AVROBIO's biggest rival. Immune Design was founded in 2008, and is headquartered in Seattle, Washington. Like AVROBIO, Immune Design also works within the Biotechnology sector. Immune Design generates $1M more revenue vs. AVROBIO.

Juno Therapeutics is one of AVROBIO's top competitors. Juno Therapeutics's headquarters is in Seattle, Washington, and was founded in 2013. Like AVROBIO, Juno Therapeutics also works within the Biotechnology sector. Juno Therapeutics generates 9,002% of AVROBIO's revenue.

Altor BioScience is seen as one of AVROBIO's top competitors. Altor BioScience is a Private company that was founded in 2002 in Miramar, Florida. Altor BioScience operates in the Biotechnology industry. Compared to AVROBIO, Altor BioScience has 81 more employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is bluebird bio a competitor of AVROBIO?

Quarterly and Annual Revenue

Coming soon for AVROBIO!

Annual Revenue

$1.2M

AVROBIO's revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 36.6M.

Acquisitions

No recent acquisitions found related to AVROBIO

AVROBIO Funding History

$7.5M$266.9M

Since AVROBIO was founded in 2015, it has participated in 5 rounds of funding. In total AVROBIO has raised $266.9M. AVROBIO's last funding round was on Jun 2018 for a total of $99.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jun 2018
$99.7M

IPO
Jun 2018
$99.7M
-
Series B
Jan 2018
$60M
Series A
Jul 2016
$7.5M
Seed
Feb 2016
--

Since AVROBIO was founded in 2015, it has participated in 5 rounds of funding. In total AVROBIO has raised $266.9M. AVROBIO's last funding round was on Jun 2018 for a total of $99.7M

Investments

No recent investments found related to AVROBIO

AVROBIO News

December 4, 2020BioSpace

AVROBIO Announces Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free p... See more »
December 4, 2020Zolmax News

Autolus Therapeutics (NASDAQ:AUTL) versus AVROBIO (NASDAQ:AVRO) Financial Review

AVROBIO (NASDAQ:AVRO) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, bu... See more »
November 25, 2020Boston Citybizlist

AVROBIO Closes Underwritten Public Offering

November 17, 2020MarketScreener

Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

(marketscreener.com) Three months post-gene therapy, first patient in Gaucher trial shows reductions ... See more »
November 17, 2020MarketScreener

2020 Virtual R&D Day Presentation

(marketscreener.com) R&D Day N O V E M B E R 2 0 2 0 Disclaimer This presentation has been prepared b... See more »

AVROBIO Press Releases

November 13, 2018GlobeNewswire

AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update

During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application f... See more »

Social Media

Headquarters

One Kendall Square Suite 201, Building 300

Cambridge, Massachusetts02139

617-914-8420

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

AVROBIO develops and commercializes step-change cell and gene therapies for the treatment of cancer and rare diseases. AVROBIO was founded in 2015. AVROBIO's headquarters is located in Cambridge, Massachusetts, USA 02139. It has raised 266.9M in 5 rou...

CEO

AVROBIO's President & CEO, Geoff MacKay, currently has an approval rating of 98%. AVROBIO's primary competitors are Immune Design, Juno Therapeutics & Altor BioScience.

Website

avrobio.com

Frequently Asked Questions about AVROBIO

  1. When was AVROBIO founded?

    AVROBIO was founded in 2015
  2. Who is AVROBIO's CEO?

    AVROBIO's CEO is Geoff MacKay
  3. How much revenue does AVROBIO generate?

    AVROBIO generates $1.2M in revenue
  4. How much funding does AVROBIO have?

    AVROBIO has historically raised $266.9M in funding
  1. Where is AVROBIO's headquarters?

    AVROBIO's headquarters is in Cambridge Massachusetts, USA
  2. How many employees does AVROBIO have?

    AVROBIO has 49 employees
  3. What sector does AVROBIO operate in?

    AVROBIO is in Biotechnology
  4. Who are AVROBIO's competitors?

    AVROBIO's top competitors are Immune Design, Juno Therapeutics, Altor BioScience